Pfizer’s COVID-19 Vaccine Data In Young Children Could Place US FDA In Awkward Position Again
The agency is considering how to move forward as Pfizer studies a third shot after missing an efficacy endpoint in children age 2 to 5.
The agency is considering how to move forward as Pfizer studies a third shot after missing an efficacy endpoint in children age 2 to 5.